TEVOGEN BIO HOLDINGS INC. - COMMON STOCK

Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions

15 10 2024 14:30:57 提供 Nasdaq GlobeNewswire

Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use

15 10 2024 11:36:13 提供 Nasdaq GlobeNewswire

Tevogen CEO Reaffirms the Company’s Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections

14 10 2024 18:43:44 提供 Nasdaq GlobeNewswire

Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024

11 10 2024 15:59:39 提供 Nasdaq GlobeNewswire

Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID

11 10 2024 12:12:04 提供 Nasdaq GlobeNewswire

Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation

08 10 2024 14:40:05 提供 Nasdaq GlobeNewswire

Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation

24 9 2024 11:09:57 提供 Nasdaq GlobeNewswire

Tevogen Bio Secures $6 Million Series C Preferred Stock Investment

22 8 2024 09:00:00 提供 Nasdaq GlobeNewswire

CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

15 8 2024 12:17:01 提供 Nasdaq GlobeNewswire

Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

15 8 2024 09:00:00 提供 Nasdaq GlobeNewswire

Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health

14 8 2024 09:00:00 提供 Nasdaq GlobeNewswire

Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities

09 8 2024 11:00:00 提供 Nasdaq GlobeNewswire

Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback

11 7 2024 12:21:21 提供 Nasdaq GlobeNewswire

Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian

10 7 2024 08:05:00 提供 Nasdaq GlobeNewswire

Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility

08 7 2024 16:07:16 提供 Nasdaq GlobeNewswire

Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities

26 6 2024 12:46:13 提供 Nasdaq GlobeNewswire

Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances

25 6 2024 08:05:00 提供 Nasdaq GlobeNewswire

Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference

18 6 2024 15:17:05 提供 Nasdaq GlobeNewswire

Tevogen Bio Set to Join Russell 3000® Index

12 6 2024 15:45:00 提供 Nasdaq GlobeNewswire

Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

11 6 2024 15:30:00 提供 Nasdaq GlobeNewswire